Home » Health and medicine » Biopharma » Intellia Therapeutics Announces Pricing of Initial Public Offering

Intellia Therapeutics Announces Pricing of Initial Public Offering

FOR IMMEDIATE RELEASE — CAMBRIDGE, Mass., May 5, 2016 – Intellia Therapeutics, Inc. (”Intellia Therapeutics” or “Intellia”) a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $18 per share. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the initial public offering price, less the underwriting discount. Intellia’s common stock is expected to begin trading on the NASDAQ Global Market under the ticker symbol "NTLA" on May 6, 2016.

Credit Suisse, Jefferies LLC, and Leerink Partners are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 5, 2016. The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained, when available, from: Credit Suisse Securities (USA) LLC, Attn: Prospectus Dept., One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037 or by email at newyork.prospectus@credit-suisse.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547- 6340 or by email at Prospectus_Department@Jeffries.com; or Leerink Partners LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800- 808-7525 ext. 6142 or by email at Syndicate@Leerink.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Intellia Therapeutics Intellia Therapeutics is a leading gene editing company focused on the development of proprietary and potentially curative therapeutics using CRISPR/Cas9 technology.


Jennifer Mound Smoter
Chief External Affairs & Communications Officer
224-804- 4462

John Graziano
Trout Group
646- 378-2942

Chad Rubin
Trout Group
646 378-2947


Press Release

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.